Sep 29, 2019
Novartis Kisqali® delivers consistently superior overall survival - MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
Sep 02, 2019
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
Aug 16, 2019
Global Communicable Disease Market Research Report 2019 Featuring Abbott Laboratories, AbbVie., GlaxoSmithKline, Novartis and Pfizer
Jul 30, 2019
Global Vision Care Market Size, Trends and Forecast Report 2019-2023 with Profiles of Bausch Health Companies, Johnson & Johnson, Novartis, The Cooper Companies
Jun 03, 2019
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
Jun 01, 2019
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
May 24, 2019
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
May 24, 2019
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
May 13, 2019
The Global Rickets Treatment Market to 2023; Led by F. Hoffmann-La Roche, Merck, Novartis, Pfizer, and Sanofi
May 07, 2019
New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1
May 05, 2019
AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
Apr 26, 2019
Global HDAC (histone deacetylase) Inhibitors Market to 2023 Featuring Celgene, Merck & Co, Novartis, Shenzhen Chipscreen Biosciences, & Spectrum Pharmaceuticals
Apr 15, 2019
Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
Mar 29, 2019
Global Antidiuretic Drugs Market 2019-2023 with Avadel, CSL Limited, Ferring B.V., Novartis & Sanofi Dominating
Mar 27, 2019
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Feb 19, 2019
Alcon Debuts iLux® MGD Treatment System for Personalized Therapy for Dry Eye Disease at SECO International 2019 Annual Meeting
Jan 08, 2019
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
Dec 06, 2018
Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
Dec 02, 2018
Real-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies
Dec 01, 2018
Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers